Euthymics is developing amitifadine (ATN) for central nervous system disorders of significant unmet medical need including alcohol use disorder (AUD) and smoking cessation. About Addiction
Serotonin, norepinephrine, and dopamine are three important neurotransmitters found in the brain and are associated with mood, focus, cognition and pleasure. By overlaying norepinephrine and dopamine on the role of serotonin, it is believed that ATN has the potential to reduce cravings, impulsivity and withdrawal effects associated with discontinuing addictive substances. Science
Several phase 2 randomized clinical trials of amitifadine (ATN) for AUD are being planned at National Institute on Alcohol Abuse and Alcoholism (NIAAA) Centers of Excellence. Plans are to design and run a pilot study of ATN to aid smoking cessation to be funded by the National Institute on Drug Abuse (NIDA). Amitifadine
Euthymics, located in Cambridge, Massachusetts, is a privately held company. Euthymics Bioscience has been funded in a venture capital investment by Novartis Venture Fund, Venture Investors, Tekla Capital Management, GBS Venture Partners, State of Wisconsin Investment Board (SWIB) and Timothy J. Barberich. Key members of the leadership team are experienced drug developers and have been involved in developing several successful neuroscience medications.